{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:35:11Z","timestamp":1777386911731,"version":"3.51.4"},"reference-count":11,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,7,12]],"date-time":"2014-07-12T00:00:00Z","timestamp":1405123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2015,1]]},"abstract":"Abstract<\/jats:title>\n \n Aims<\/jats:title>\n \n To examine whether insulin glargine can lead to better control of glycated haemoglobin (\n HbA1c<\/jats:styled-content>\n ) than that achieved by neutral protamine Hagedorn (\n NPH<\/jats:styled-content>\n ) insulin, using a protocol designed to limit nocturnal hypoglycaemia.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n The present study, the Least One Oral Antidiabetic Drug Treatment (\n LANCELOT<\/jats:styled-content>\n ) Study, was a 36\u2010week, randomized, open\u2010label, parallel\u2010arm study conducted in Europe, Asia, the Middle East and South America. Participants were randomized (1\u2009:\u20091) to begin glargine or\n NPH<\/jats:styled-content>\n , on background of metformin with glimepiride. Weekly insulin titration aimed to achieve median prebreakfast and nocturnal plasma glucose levels \u22645.5\u2009mmol\/l, while limiting values \u22644.4\u2009mmol\/l.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The efficacy population (n\u2009=\u2009701) had a mean age of 57 years, a mean body mass index of 29.8\u2009kg\/m\n 2<\/jats:sup>\n , a mean duration of diabetes of 9.2\u2009years and a mean\n HbA1c<\/jats:styled-content>\n level of 8.2% (66\u2009mmol\/mol). At treatment end,\n HbA1c<\/jats:styled-content>\n values and the proportion of participants with\n HbA1c<\/jats:styled-content>\n <7.0 % (<53\u2009mmol\/mol) were not significantly different for glargine [7.1 % (54\u2009mmol\/mol) and 50.3%] versus\n NPH<\/jats:styled-content>\n [7.2 % (55\u2009mmol\/mol) and 44.3%]. The rate of symptomatic nocturnal hypoglycaemia, confirmed by plasma glucose \u22643.9 or \u22643.1\u2009mmol\/l, was 29 and 48% less with glargine than with\n NPH<\/jats:styled-content>\n insulin. Other outcomes were similar between the groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n Insulin glargine was not superior to\n NPH<\/jats:styled-content>\n insulin in improving glycaemic control. The insulin dosing algorithm was not sufficient to equalize nocturnal hypoglycaemia between the two insulins. This study confirms, in a globally heterogeneous population, the reduction achieved in nocturnal hypoglycaemia while attaining good glycaemic control with insulin glargine compared with\n NPH<\/jats:styled-content>\n , even when titrating basal insulin to prevent nocturnal hypoglycaemia rather than treating according to normal fasting glucose levels.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12329","type":"journal-article","created":{"date-parts":[[2014,6,24]],"date-time":"2014-06-24T11:27:13Z","timestamp":1403609233000},"page":"15-22","source":"Crossref","is-referenced-by-count":19,"title":["Modulation of insulin dose titration using a hypoglycaemia\u2010sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin\u2010na\u00efve people with type 2 diabetes"],"prefix":"10.1111","volume":"17","author":[{"given":"P. D.","family":"Home","sequence":"first","affiliation":[{"name":"Institute for Cellular Medicine\u00a0\u2013\u00a0Diabetes Newcastle University Newcastle upon Tyne UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. B.","family":"Bolli","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Perugia Perugia Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mathieu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology University Hospital Gasthuisberg Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Deerochanawong","sequence":"additional","affiliation":[{"name":"Rajavithi Hospital, College of Medicine Rangsit University, Ministry of Public Health Bangkok Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Landgraf","sequence":"additional","affiliation":[{"name":"Sanofi Frankfurt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Candelas","sequence":"additional","affiliation":[{"name":"Sanofi Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Pilorget","sequence":"additional","affiliation":[{"name":"Sanofi Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.\u2010P.","family":"Dain","sequence":"additional","affiliation":[{"name":"Sanofi Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. C.","family":"Riddle","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University Portland OR USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,7,12]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"International Diabetes Federation. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. International Diabetes Federation Web site.2012. Available from URL:https:\/\/www.aace.com\/files\/dm\u2010guidelines\u2010ccp.pdf. Accessed 3 April 2013."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"e_1_2_7_4_1","unstructured":"NICE. Blood\u2010glucose\u2010lowering therapy for type 2 diabetes. Available from URL:http:\/\/pathways.nice.org.uk\/pathways\/diabetes\/blood\u2010glucose\u2010lowering\u2010therapy\u2010for\u2010type\u20102\u2010diabetes. Accessed 6 December2013."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP.13.S1.1"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc05-1365"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3080"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01232.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2011.0022"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.08.020"},{"key":"e_1_2_7_11_1","first-page":"111","volume-title":"Handbook of Psychology and Diabetes","author":"Bradley C","year":"1994"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/193229681300700323"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12329","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.12329","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.12329","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12329","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:13:54Z","timestamp":1761862434000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,12]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1111\/dom.12329"],"URL":"https:\/\/doi.org\/10.1111\/dom.12329","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,12]]}}}